BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21861962)

  • 1. Natural history and outcome of mucinous carcinoma of the ovary.
    Schiavone MB; Herzog TJ; Lewin SN; Deutsch I; Sun X; Burke WM; Wright JD
    Am J Obstet Gynecol; 2011 Nov; 205(5):480.e1-8. PubMed ID: 21861962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
    Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
    Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy.
    Bamias A; Psaltopoulou T; Sotiropoulou M; Haidopoulos D; Lianos E; Bournakis E; Papadimitriou C; Rodolakis A; Vlahos G; Dimopoulos MA
    Cancer; 2010 Mar; 116(6):1462-8. PubMed ID: 20108307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.
    Chan JK; Teoh D; Hu JM; Shin JY; Osann K; Kapp DS
    Gynecol Oncol; 2008 Jun; 109(3):370-6. PubMed ID: 18395777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved survival for fallopian tube cancer: a comparison of clinical characteristics and outcome for primary fallopian tube and ovarian cancer.
    Wethington SL; Herzog TJ; Seshan VE; Bansal N; Schiff PB; Burke WM; Cohen CJ; Wright JD
    Cancer; 2008 Dec; 113(12):3298-306. PubMed ID: 19006196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical factors and biomarkers in ovarian tumors development.
    Vrabie CD; Petrescu A; Waller M; Dina I
    Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and prognosis of mucinous tumors of the ovary.
    Kikkawa F; Nawa A; Kajiyama H; Shibata K; Ino K; Nomura S
    Gynecol Oncol; 2006 Oct; 103(1):171-5. PubMed ID: 16546243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis.
    Rauh-Hain JA; Diver EJ; Clemmer JT; Bradford LS; Clark RM; Growdon WB; Goodman AK; Boruta DM; Schorge JO; del Carmen MG
    Gynecol Oncol; 2013 Oct; 131(1):46-51. PubMed ID: 23906658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications.
    Köbel M; Kalloger SE; Santos JL; Huntsman DG; Gilks CB; Swenerton KD
    Gynecol Oncol; 2010 Jan; 116(1):50-6. PubMed ID: 19822358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant and borderline epithelial ovarian tumors in the pediatric and adolescent population.
    Nasioudis D; Alevizakos M; Holcomb K; Witkin SS
    Maturitas; 2017 Feb; 96():45-50. PubMed ID: 28041594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival among U.S. women with invasive epithelial ovarian cancer.
    McGuire V; Jesser CA; Whittemore AS
    Gynecol Oncol; 2002 Mar; 84(3):399-403. PubMed ID: 11855877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histologic subtypes and laterality of primary epithelial ovarian tumors.
    Boger-Megiddo I; Weiss NS
    Gynecol Oncol; 2005 Apr; 97(1):80-3. PubMed ID: 15790441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum.
    Kang H; O'Connell JB; Maggard MA; Sack J; Ko CY
    Dis Colon Rectum; 2005 Jun; 48(6):1161-8. PubMed ID: 15868237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival analysis in advanced epithelial ovarian carcinoma in relation to proliferative index of MIB-1 immunostaining.
    Kritpracha K; Hanprasertpong J; Chandeying V; Dechsukhum C; Geater A
    J Obstet Gynaecol Res; 2005 Jun; 31(3):268-76. PubMed ID: 15916666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.
    Storey DJ; Rush R; Stewart M; Rye T; Al-Nafussi A; Williams AR; Smyth JF; Gabra H
    Cancer; 2008 May; 112(10):2211-20. PubMed ID: 18344211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary.
    Shimada M; Kigawa J; Ohishi Y; Yasuda M; Suzuki M; Hiura M; Nishimura R; Tabata T; Sugiyama T; Kaku T
    Gynecol Oncol; 2009 Jun; 113(3):331-4. PubMed ID: 19275957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
    Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
    Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fertility-sparing surgery in young women with mucinous adenocarcinoma of the ovary.
    Kajiyama H; Shibata K; Mizuno M; Nawa A; Mizuno K; Matsuzawa K; Kawai M; Hosono S; Nagasaka T; Kikkawa F
    Gynecol Oncol; 2011 Aug; 122(2):334-8. PubMed ID: 21575985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse and survival in early-stage ovarian cancer.
    Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
    Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.